A novel test for IGT utilizing metabolite markers of glucose tolerance

Journal of Diabetes Science and Technology

Volumn 9, Issue 1, 2015, Pages 69-76

  Cobb, Jeff ^a   Eckhart, Andrea ^a   Perichon, Regis ^a   Wulff, Jacob ^a   Mitchell, Matthew ^a   Adam, Klaus Peter ^a   Wolfert, Robert ^a   Button, Eric ^a   Lawton, Kay ^a   Elverson, Robert ^a   Carr, Bernadette ^b   Sinnott, Margaret ^b   Ferrannini, Ele ^c  

^a METABOLON INC   (United States)

^b Vhi Healthcare Ltd   (Ireland)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

biomarkers; IGT; metabolomics; OGTT

Indexed keywords

2 AMINOADIPIC ACID; 2 OXOBUTYRIC ACID; 2 OXOGLUTARIC ACID; 2 OXOISOCAPROIC ACID; 2 OXOISOVALERIC ACID; 3 HYDROXY 2 METHYLPROPIONIC ACID; 3 HYDROXYBUTYRIC ACID; 3 METHYL 2 OXOPENTANOIC ACID; ALPHA HYDROXYBUTYRIC ACID; BIOLOGICAL MARKER; CARNITINE; CREATINE; GLUCOSE; GLYCEROPHOSPHORYLCHOLINE; GLYCINE; HYDROXYBUTYRIC ACID; HYDROXYISOVALEROYL CARNITINE; ISOLEUCINE; LEUCINE; LINOLEOYLGLYCEROPHOSPHOCHOLINE; OLEIC ACID; OXOACID; PANTOTHENIC ACID; PHENYLALANINE; SERINE; STABLE ISOTOPE; TRIGONELLINE; TYROSINE; UNCLASSIFIED DRUG; VALINE; GLUCOSE BLOOD LEVEL;

ADULT; AREA UNDER THE CURVE; ARTICLE; DILUTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PREDICTIVE VALUE; QUANTITATIVE ASSAY; QUANTOSE IMPAIRED GLUCOSE TOLERANCE TEST; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; AGED; ANALYSIS; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; RISK FACTOR; STANDARDS;

ADULT; AGED; BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 84947934572     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296814553622     Document Type: Article

References (38)

1. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
2. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37:S14-S80.
3. Cederberg H, Saukkonen T, Laakso M, et al. Postchallenge glucose, A1C, and fasting glucose as predictors of type 2 diabetes and cardiovascular disease: A 10-year prospective cohort study. Diabetes Care. 2010;33:2077-2083.
4. Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: The Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care. 2010;33: 2104-2109.
5. Ferrannini E, Gastaldelli A, Iozzo P. Pathophysiology of prediabetes. Med Clin North Am. 2011;95:327-339.
6. Borg R, Kuenen JC, Carstensen B, et al. Associations between features of glucose exposure and A1C: The A1CDerived Average Glucose (ADAG) study. Diabetes. 2010;59: 1585-1590.
7. Rich PA, Shaefer CF, Parkin CG, Edelman SV. Using a quantitative measure of diabetes risk in clinical practice to target and maximize diabetes prevention interventions. Clin Diabetes. 2013;31:82-89.
8. Schtker B, Raum E, Rothenbacher D, Mler H, Brenner H. Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening. Eur J Epidemiol. 2011;26:779-787.
9. Morris DH, Khunti K, Achana F, et al. Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: A meta-Analysis. Diabetologia. 2013;56:1489-1493.
10. Gillies CL, Abrams KR, Lambert PC, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-Analysis. BMJ. 2007;334:299.
11. Ferrannini E, Natali A, Camastra S, et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes. 2013;62:1730-1737.
12. Cobb J, Gall W, Adam KP, et al. A novel fasting blood test for insulin resistance and prediabetes. J Diabetes Sci Technol. 2013;1;7:100-110.
13. Hills SA, Balkau B, Coppack SW, et al. The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia. 2004;47:566-570.
14. Ferrannini E1, Natali A, Muscelli E, et al. Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: The RISC Study. Diabetologia. 2011;54(6):1507-1516.
15. Lindstr J, Tuomilehto J. The diabetes risk score: A practical tool to predict type 2 diabetes risk. Diabetes Care. 2003; 26(3):725-731.
16. Andersen GS, Thybo T, Cederberg H, et al. The DEXLIFE study methods: identifying novel candidate biomarkers that predict progression to type 2 diabetes in high risk individuals [published online ahead of print July 27, 2014]. Diabetes Res Clin Pract.
17. Groop L, Forsblom C, Lehtovirta M, et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes. 1996;45(11):1585-1593.
18. Stancov A, Javorsk M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6, 414 Finnish men. Diabetes. 2009;58(5):1212-1221.
19. Wtz P, Tiainen M, Minen VP, et al. Circulating metabolite predictors of glycemia in middle-Aged men and women. Diabetes Care. 2012;35(8):1749-1756.
20. Menni C, Fauman E, Erte I, et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes. 2013;62(12):4270-4276.
21. Wang-Sattler R, Yu Z, Herder C, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8:615.
22. Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62(2):639-648.
23. Wang TJ, Ngo D, Psychogios N, et al. 2-Aminoadipic acid is a biomarker for diabetes risk. J Clin Invest. 2013;123(10): 4309-4317.
24. Gall WE, Beebe K, Lawton KA, et al. alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLOS ONE. 2010;5(5):e10883.
25. Liaw A, Wiener M. Classification and regression by random forest. R News. 2002;2(3):18-22.
26. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. http://www.R-project.org/.
27. Robin X, Turck N, Hainard A, et al. pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.
28. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 1988;44:837-845.
29. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. http://www.cdc. gov/diabetes/pubs/factsheet11/tables3-4.htm.
30. Ferrannini E, Massari M, Nannipieri M, Natali A, Ridaura RL, Gonzales-Villalpando C. Plasma glucose levels as predictors of diabetes: The Mexico City diabetes study. Diabetologia. 2009;52:818-824.
31. Nelson KM, Boyko EJ. Third National Health and Nutrition Examination Survey. Predicting impaired glucose tolerance using common clinical information: data from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2003;26:2058-2062.
32. Meigs JB, Williams K, Sullivan LM, et al. Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. Diabetes Care. 2004;27:1417-1426.
33. El Bassuoni EA, Ziemer DC, Kolm P, et al. The "metabolic syndrome" is less useful than random plasma glucose to screen for glucose intolerance. Prim Care Diabetes. 2008;2:147-153.
34. Hadaegh F, Harati H, Ghasemi A, et al. Using common clinical data improves the prediction of abnormal glucose tolerance by the new criteria of impaired fasting glucose: Tehran lipid and glucose study. Diabetes Res Clin Pract. 2007;77:459-464.
35. Uzunlulu M, Oguz A, Yorulmaz E. In which patients will performing an oral glucose tolerance test yield the highest rate of positive results? Acta Clin Belg. 2006;61:64-68.
36. Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P. Impact of A1C screening criterion on the diagnosis of prediabetes among U.S. adults. Diabetes Care. 2010;33(10): 2190-2195.
37. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7): 412-419.
38. McGarry JD, What if Minkowski had been ageusic? An alternative angle on diabetes. Science. 1992;258(5083):766-770.